Donor Serostatus Has an Impact on Cytomegalovirus-Specific Immunity, Cytomegaloviral Disease Incidence, and Survival in Seropositive Hematopoietic Cell Transplant Recipients

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 4, 2011, Pages 574-585

  Ugarte Torres, Alejandra ^a   Hoegh Petersen, Mette ^a   Liu, Yiping ^a   Zhou, Feng ^a   Williamson, Tyler S ^b   Quinlan, Diana ^c   Sy, Sarah ^a   Roa, Lina ^a   Khan, Faisal ^a   Fonseca, Kevin ^d   Russell, James A ^c   Storek, Jan ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c ALBERTA HEALTH SERVICES   (Canada)

^d PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

Author keywords

Cytomegalovirus; Hematopoietic cell transplantation; T cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; THYMOCYTE ANTIBODY; VIRUS DNA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; RABBIT; RECIPIENT; T LYMPHOCYTE; VIRUS IMMUNITY; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RABBITS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; VACCINATION;

EID: 79952619324     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.07.020     Document Type: Article

References (50)

1. Maury S., Mary J.Y., Rabian C., et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol 2001, 115:630-641.
2. Boeckh M., Nichols W.G., Papanicolaou G., Rubin R., Wingard J.R., Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003, 9:543-558.
3. Reusser P., Fisher L.D., Buckner C.D., Thomas E.D., Meyers J.D. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood 1990, 75:1888-1894.
4. Li C.R., Greenberg P.D., Gilbert M.J., Goodrich J.M., Riddell S.R. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994, 83:1971-1979.
5. Ljungman P., Lonnqvist B., Wahren B., Ringden O., Gahrton G. Lymphocyte responses after cytomegalovirus infection in bone marrow transplant recipients-a one-year follow-up. Transplantation 1985, 40:515-520.
6. Reusser P., Riddell S.R., Meyers J.D., Greenberg P.D. Cytotoxic T-lymphocyte response to CMV after human allogeneic BMT: pattern of recovery and correlation with CMV infection and disease. Blood 1991, 78:1373-1380.
7. Gratama J.W., Brooimans R.A., van der Holt B., et al. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry B Clin Cytom 2008, 74:211-220.
8. Foster A.E., Gottlieb D.J., Sartor M., Hertzberg M.S., Bradstock K.F. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2002, 8:501-511.
9. Einsele H., Ehninger G., Steidle M., et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993, 82:1672-1678.
10. Hakki M., Riddell S.R., Storek J., et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003, 102:3060-3067.
11. Pourgheysari B., Piper K.P., McLarnon A., et al. Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant 2009, 43:853-861.
12. Boland G.J., Vlieger A.M., Ververs C., De Gast G.C. Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation. Clin Exp Immunol 1992, 88:506-511.
13. Avetisyan G., Aschan J., Hagglund H., Ringden O., Ljungman P. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 2007, 40:865-869.
14. Ljungman P., Perez-Bercoff L., Jonsson J., et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006, 91:78-83.
15. Ozdemir E., Saliba R.M., Champlin R.E., et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007, 40:125-136.
16. Patel S.R., Ridwan R.U., Ortin M. Cytomegalovirus reactivation in pediatric hemopoietic progenitors transplant: a retrospective study on the risk factors and the efficacy of treatment. J Pediatr Hematol Oncol 2005, 27:411-415.
17. Zhou W., Longmate J., Lacey S.F., et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 2009, 113:6465-6476.
18. Nichols W.G., Corey L., Gooley T., Davis C., Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002, 185:273-282.
19. Ljungman P., Brand R., Einsele H., Frassoni F., Niederwieser D., Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003, 102:4255-4260.
20. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
21. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003, 102:1224-1231.
22. Gandhi M.K., Wills M.R., Okecha G., et al. Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation. Blood 2003, 102:3427-3438.
23. Chalandon Y., Degermann S., Villard J., et al. Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. Blood 2006, 107:389-396.
24. Saito T., Kanda Y., Nakai K., et al. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation. Bone Marrow Transplant 2003, 32:601-608.
25. Kalwak K., Moson I., Cwian J., et al. A prospective analysis of immune recovery in children following allogeneic transplantation of t-cell-depleted or non-T-cell-depleted hematopoietic cells from HLA-disparate family donors. Transplant Proc 2003, 35:1551-1555.
26. Meijer E., Bloem A.C., Dekker A.W., Verdonck L.F. Effect of antithymocyte globulin on quantitative immune recovery and graft-versus-host disease after partially T-cell-depleted bone marrow transplantation: a comparison between recipients of matched related and matched unrelated donor grafts. Transplantation 2003, 75:1910-1913.
27. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
28. Russell J.A., Turner A.R., Larratt L., et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 2007, 13:299-306.
29. Russell J.A., Duan Q., Chaudhry M.A., et al. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biol Blood Marrow Transplant 2008, 14:888-895.
30. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
31. Gerna G., Zipeto D., Percivalle E., et al. Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients. J Infect Dis 1992, 166:1236-1244.
32. Pang X.L., Chui L., Fenton J., LeBlanc B., Preiksaitis J.K. Comparison of LightCycler-based PCR, COBAS amplicor CMV monitor, and pp65 antigenemia assays for quantitative measurement of cytomegalovirus viral load in peripheral blood specimens from patients after solid organ transplantation. J Clin Microbiol 2003, 41:3167-3174.
33. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
34. Kannanganat S., Ibegbu C., Chennareddi L., Robinson H.L., Amara R.R. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007, 81:8468-8476.
35. Duvall M.G., Precopio M.L., Ambrozak D.A., et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 2008, 38:350-363.
36. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004, 159:702-706.
37. Fine J.G.R. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc 1999, 94:496-509.
38. Ringden O., Schaffer M., Le Blanc K., et al. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?. Biol Blood Marrow Transplant 2004, 10:128-134.
39. Avetisyan G., Larsson K., Aschan J., Nilsson C., Hassan M., Ljungman P. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant 2006, 38:687-692.
40. Couriel D., Canosa J., Engler H., Collins A., Dunbar C., Barrett A.J. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant 1996, 18:347-353.
41. Riddell S.R., Rabin M., Geballe A.P., Britt W.J., Greenberg P.D. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 1991, 146:2795-2804.
42. Bitmansour A.D., Waldrop S.L., Pitcher C.J., et al. Clonotypic structure of the human CD4+ memory T cell response to cytomegalovirus. J Immunol 2001, 167:1151-1163.
43. Solano C., Benet I., Clari M.A., et al. Enumeration of cytomegalovirus-specific interferongamma CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. Haematologica 2008, 93:1434-1436.
44. Widmann T., Sester U., Gartner B.C., et al. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS One 2008, 3:e3634.
45. Craddock C., Szydlo R.M., Dazzi F., et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol 2001, 112:228-236.
46. Matthes-Martin S., Lion T., Aberle S.W., et al. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplant 2003, 31:803-808.
47. Kroger N., Zabelina T., Kruger W., et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 2001, 113:1060-1071.
48. LaCorcia G., Swistak M., Lawendowski C., et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 2009, 87:966-974.
49. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007, 21:1387-1394.
50. Broers A.E., van Der Holt R., van Esser J.W., et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000, 95:2240-2245.